Is mayzent affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C9

mayzent is affected by pharmacogenetics through the CYP2C9 gene. Your genotype for this gene can change how your body processes mayzent, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in mayzent

siponimod affected by CYP2C9

Affected by CYP2C9 · FDA · Strong evidence

Read the full siponimod genetics guide →

Siponimod phenotype recommendations

Published guidance from FDA on how siponimod should be dosed or substituted based on your CYP2C9 phenotype.

Phenotype	What it means	Recommendation	Evidence
Normal Metabolizer CYP2C9	Your body processes siponimod at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Intermediate Metabolizer CYP2C9	Your body breaks down siponimod slower than normal, causing the drug to reach higher levels in your system. Your doctor will need to adjust your dose based on your specific genetic profile.	FDA Adjust dosage based on genotype. Refer to FDA labeling for specific dosing recommendations.	Strong
Poor Metabolizer CYP2C9	Your body breaks down siponimod much more slowly than normal, causing the drug to build up to potentially unsafe levels. Depending on your exact genetic profile, siponimod may need to be avoided entirely or the dose significantly reduced.	FDA Do not use in patients with CYP2C9 3/3 genotype. For other poor metabolizer genotypes, adjust dosage based on genotype. Refer to FDA labeling for specific dosing recommendations.	Strong
Indeterminate CYP2C9	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C9	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—

Source: FDA

The gene behind the guidance

CYP2C9 Cytochrome P450 2C9

CYP2C9 metabolizes warfarin, phenytoin, celecoxib, and some NSAIDs. Variants that reduce its activity are most consequential for warfarin, where even small changes in drug clearance translate into very different doses (and a real bleeding risk if missed).

Poor metabolizers need substantially lower warfarin doses to hit the same INR target.

See all drugs affected by CYP2C9 →

Browse the full drug-class: Immunosuppressants.

Related medications

Find out how your genetics affect mayzent

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.